MEDICAL RESEARCH

FDA expands use of Bristol Myers' cancer drug Yervoy

Female doctor holding application form while consulting patient

Female doctor holding application form while consulting patient

The U.S. Food and Drug Administration expanded the use of Bristol-Myers Squibb Co's skin cancer drug, Yervoy, as an additional therapy for patients with advanced melanoma.

This approval extends Yervoy's use to patients who are at a high risk of melanoma recurrence after surgery, the agency said on Wednesday.

Yervoy, administered intravenously, was originally approved in 2011 to treat late-stage melanoma that cannot be removed by surgery.

More On This...